Latin America contains at least a third of the global biodiversity , in fact, half of the countries have been classified as megadiverse: Bolivia, Brazil, Colombia, Costa Rica, Ecuador, Mexico, Peru and Venezuela) . Therefore, Latin America represents a large source of bioactive molecules and potential drug candidates (Figure ). There have been published databases containing NPs from some Latin American countries such as NaturAr (Argentina), NuBBEDB , SistematX , UEFS (Brasil), CIFPMA (Panama), PeruNPDB , (Peru), UNIIQUIM and BIOFACQUIM (Mexico). Recently, it was reviewed the present state of the art in developing Latin American NP databases and their practical applications to the drug discovery area . Multiple drug candidates have been identified from the Latin American NP databases as therapeutic agents for diseases caused by infectious agents (Chagas disease , tuberculosis , Leishmaniasis , schistosomiasis , coronavirus disease , human immunodeficiency virus infection and acquired immunodeficiency syndrome, hepatitis B and C) , pain , obesity, diabetes, hyperlipoproteinemia, cancer, and age-related diseases . Active compounds of representative medicinal plants from Latin American countries and some of its therapeutic effects described in the literature. Brazil (gallic acid and casearin x ), Costa Rica (acetogenin squamocin ) El Salvador (Genkwanin ), Mexico (3α-hydroxy masticadienoic acid and mescaline ), Panama (furoquinoline alkaloid ) and Peru (mitraphylline and benzylglucosinolate ).